Anti Angiogenesis Strategies In Cancer Therapies

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents Reviews FDA-approved anti-angiogenesis agents Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents Offers insight into the development of novel anti-angiogenesis agents and future direction in this area

Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment. Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers. This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.

This RRCR-conference-volume marks "number six" in a 20-year evolution of international conferences on the adjuvant therapy of primary breast cancer. Starting in 1978, a handful of some 80 en thusiastic breast cancer surgeons and oncologists, met in a se cluded mountain resort near st. Gallen in Eastern Switzerland, to exchange their early data of some pioneer trials on adjuvant sys temic therapy of early breast cancer, and to correlate their future research efforts to overcome the frustrating prognostic stagna tion of this dominant neoplastic disease in Western females dur ing the past decades. Repeated every 3-4 years, these St. Gallen International Conferences on Adjuvant Therapy of Primary Breast Cancer have continuously grown in numbers of partici pants and in normative, therapeutic influence by being published in major oncology journals [1-3], the last (6th) conference hav ing taken place from February 25-28, 1998 with more than 1800 attendees from over 50 countries worldwide. What is the fascination of adjuvant therapy in primary (early) breast cancer, and what has changed,during the last 3 years since March 1995, to justify another international gathering of this size, and of the world's leading experts in the field? There is no question, that providing even more effective care and designing appropriate recommendations for the multitudes of patients with so-called early breast cancer or at high risk of developing the disease, remain highly important public health goals.

Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.

This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.​

This book highlights recent developments of organic and inorganic nanomedicine that play a major role in anti-angiogenic cancer therapy. In addition, the authors present examples of nanomedicine based anti-angiogenic agents and their applications in cancer therapy. Angiogenesis is a pathophysiological phenomenon that modulates cell proliferation and cell migration and plays important roles in cancer. Anti-angiogenic nanotherapies have gained immense attention in recent times as alternative cost-effective therapies that opened a new dimension in cancer theranostics. Further the challenges of the anti-angiogenic nanotherapies and possible future perspective are detailed.

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians. Edited and written by leading experts in angiogenesis drug development Reviews recent advances in the field, such as coverage of anti-angiogenetic drugs in ovarian cancer Reports current strategies and future outlook for anti-angiogenic therapy and cardiovascular diseases